Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial
- 27 November 2023
- Vol. 119 (4) , 664-676
Abstract
Background and aims: iCanQuit is a smartphone application (app) proven efficacious for smoking cessation in a Phase III randomized controlled trial (RCT). This study aimed to measure whether medications approved by the US Food and Drug Administration (FDA) for smoking cessation would further enhance the efficacy of iCanQuit, relative to its parent trial comparator—the National Cancer Institute's (NCI's) QuitGuide app.Design: Secondary analysis of the entire parent trial sample of a two‐group (iCanQuit and QuitGuide), stratified, doubled‐blind RCT.Setting: United States.Participants: Participants who reported using an FDA‐approved cessation medication on their own (n = 619) and those who reported no use of cessation medications (n = 1469).Interventions: Participants were randomized to receive iCanQuit app or NCI's QuitGuide app.Measurements: Use of FDA‐approved medications was measured at 3 months post‐randomization. Smoking cessation outcomes were measured at 3, 6 and 12 months. The primary outcome was 12‐month self‐reported 30‐day point prevalence abstinence (PPA).Findings: The data retention rate at the 12‐month follow‐up was 94.0%. Participants were aged 38.5 years, 71.0% female, 36.6% minority race/ethnicity, 40.6% high school or less education, residing in all 50 US States and smoking 19.2 cigarettes/day. The 29.6% of all participants who used medications were more likely to choose nicotine replacement therapy (NRT; 78.8%) than other cessation medications (i.e. varenicline or bupropion; 18.3 and 10.5%, respectively) and use did not differ by app treatment assignment (all P > 0.05). There was a significant (P = 0.049) interaction between medication use and app treatment assignment on PPA. Specifically, 12‐month quit rates were 34% for iCanQuit versus 20% for QuitGuide [odds ratio (OR) = 2.36, 95% confidence interval (CI) = 1.59, 3.49] among participants reporting any medication use, whereas among participants reporting no medication use, quit rates were 28% for iCanQuit versus 22% for QuitGuide (OR = 1.41, 95% CI = 1.09, 1.82). Results were stronger for those using only NRT: 40% quit rates for iCanQuit versus 18% quit rates for QuitGuide (OR = 3.57, 95% CI = 2.20, 5.79).Conclusions: The iCanQuit smartphone app for smoking cessation was more efficacious than the QuitGuide smartphone app, regardless of whether participants used medications to aid cessation. Smoking cessation medications, especially nicotine replacement therapy, might enhance the efficacy of the iCanQuit app.Keywords
Funding Information
- National Cancer Institute (R01CA192849)
This publication has 55 references indexed in Scilit:
- Acceptance and Commitment Therapy and Contextual Behavioral Science: Examining the Progress of a Distinctive Model of Behavioral and Cognitive TherapyBehavior Therapy, 2013
- Costs of Giving Out Free Nicotine Patches Through a Telephone Quit LineJournal of Public Health Management & Practice, 2011
- Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic reviewNicotine & Tobacco Research, 2010
- A Framework for Public Health Action: The Health Impact PyramidAmerican Journal of Public Health, 2010
- Missing Data Analysis: Making It Work in the Real WorldAnnual Review of Psychology, 2009
- Comparison of the Quick Drinking Screen and the Alcohol Timeline Followback with Outpatient Alcohol AbusersSubstance Use & Misuse, 2008
- A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 UpdateAmerican Journal of Preventive Medicine, 2008
- Acceptance-based treatment for smoking cessationBehavior Therapy, 2004
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991
- The CES-D ScaleApplied Psychological Measurement, 1977